AU2014230812B2 - Process for making benzoxazepin compounds - Google Patents

Process for making benzoxazepin compounds Download PDF

Info

Publication number
AU2014230812B2
AU2014230812B2 AU2014230812A AU2014230812A AU2014230812B2 AU 2014230812 B2 AU2014230812 B2 AU 2014230812B2 AU 2014230812 A AU2014230812 A AU 2014230812A AU 2014230812 A AU2014230812 A AU 2014230812A AU 2014230812 B2 AU2014230812 B2 AU 2014230812B2
Authority
AU
Australia
Prior art keywords
reacting
bromo
methyl
acid
iii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014230812A
Other languages
English (en)
Other versions
AU2014230812A1 (en
AU2014230812A8 (en
Inventor
Remy Angelaud
Danial R. Beaudry
Diane E. Carrera
Sushant Malhotra
Travis Remarchuk
Frederic St-Jean
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of AU2014230812A1 publication Critical patent/AU2014230812A1/en
Publication of AU2014230812A8 publication Critical patent/AU2014230812A8/en
Application granted granted Critical
Publication of AU2014230812B2 publication Critical patent/AU2014230812B2/en
Priority to AU2016204432A priority Critical patent/AU2016204432B2/en
Priority to AU2018201393A priority patent/AU2018201393A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2014230812A 2013-03-13 2014-03-12 Process for making benzoxazepin compounds Ceased AU2014230812B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2016204432A AU2016204432B2 (en) 2013-03-13 2016-06-28 Process for making benzoxazepin compounds
AU2018201393A AU2018201393A1 (en) 2013-03-13 2018-02-27 Process for making benzoxazepin compounds

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361779619P 2013-03-13 2013-03-13
US61/779,619 2013-03-13
PCT/EP2014/054786 WO2014140073A1 (en) 2013-03-13 2014-03-12 Process for making benzoxazepin compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2016204432A Division AU2016204432B2 (en) 2013-03-13 2016-06-28 Process for making benzoxazepin compounds

Publications (3)

Publication Number Publication Date
AU2014230812A1 AU2014230812A1 (en) 2015-09-03
AU2014230812A8 AU2014230812A8 (en) 2015-09-10
AU2014230812B2 true AU2014230812B2 (en) 2016-04-07

Family

ID=50241450

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2014230812A Ceased AU2014230812B2 (en) 2013-03-13 2014-03-12 Process for making benzoxazepin compounds
AU2016204432A Ceased AU2016204432B2 (en) 2013-03-13 2016-06-28 Process for making benzoxazepin compounds
AU2018201393A Abandoned AU2018201393A1 (en) 2013-03-13 2018-02-27 Process for making benzoxazepin compounds

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2016204432A Ceased AU2016204432B2 (en) 2013-03-13 2016-06-28 Process for making benzoxazepin compounds
AU2018201393A Abandoned AU2018201393A1 (en) 2013-03-13 2018-02-27 Process for making benzoxazepin compounds

Country Status (15)

Country Link
US (1) US9303043B2 (enExample)
EP (3) EP2970329A1 (enExample)
JP (6) JP6363120B2 (enExample)
KR (3) KR20180070715A (enExample)
CN (2) CN105377856B (enExample)
AR (1) AR095365A1 (enExample)
AU (3) AU2014230812B2 (enExample)
BR (1) BR112015020716A2 (enExample)
CA (6) CA2897618A1 (enExample)
IL (1) IL240793A0 (enExample)
MX (1) MX2015011438A (enExample)
NZ (1) NZ711192A (enExample)
RU (2) RU2018109979A (enExample)
SG (2) SG10201706760YA (enExample)
WO (1) WO2014140073A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9266903B2 (en) * 2013-12-16 2016-02-23 Genentech, Inc. Polymorphs of 2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazole-5-yl)-5,6-dihydrobenzo[F]imidazo [1,2-D][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide, methods of production, and pharmaceutical uses thereof
CN111909173B (zh) * 2015-07-02 2025-03-04 豪夫迈·罗氏有限公司 苯并氧氮杂䓬噁唑烷酮化合物及其使用方法
JP6522807B2 (ja) 2015-07-02 2019-05-29 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ベンゾオキサゼピンオキサゾリジノン化合物及び使用方法
CN105906635A (zh) * 2016-06-08 2016-08-31 上海大学 全氟烷基苯并氮杂*并喹喔啉衍生物及其合成方法
EP3492452B1 (en) * 2016-07-29 2022-08-31 Japan Tobacco Inc. Production method for pyrazole-amide compound
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
PL3851441T3 (pl) 2016-12-15 2023-11-06 F. Hoffmann-La Roche Ag Proces otrzymywania (S)-2-((2-((S)-4-(difluorometylo)-2-oksooksazolidyn-3-ylo)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oksazepin-9-ylo)amino)propanamidu
CN108752237A (zh) * 2018-07-05 2018-11-06 四川青木制药有限公司 一种对氨基苯甲脒盐酸盐的新制备方法
BR112021011894A2 (pt) 2018-12-21 2021-09-08 Daiichi Sankyo Company, Limited Composição farmacêutica

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274327B1 (en) 1992-04-13 2001-08-14 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
GB9208135D0 (en) 1992-04-13 1992-05-27 Ludwig Inst Cancer Res Polypeptides having kinase activity,their preparation and use
US5846824A (en) 1994-02-07 1998-12-08 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
ES2205944T3 (es) * 1998-10-23 2004-05-01 Dow Agrosciences Llc Compuestos de 3-(fenil sustituido)-5-(ciclopropil sustituido)-1,2,4-triazol.
HUP0400164A2 (hu) 2001-07-12 2004-07-28 Avecia Ltd. Mikrokapszulázott katalizátor, eljárás előállítására és alkalmazása
CA2463441A1 (en) * 2001-10-12 2003-05-08 Bayer Pharmaceuticals Corporation Phenyl substituted 5-membered nitrogen containing heterocycles for the treatment of obesity
EP1945222B1 (en) 2005-11-02 2012-12-26 Bayer Pharma Aktiengesellschaft Pyrrolo[2,1-f] [1,2,4]-triazin-4-ylamines as igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
EA016527B1 (ru) * 2006-10-23 2012-05-30 ЭсДжиЭкс ФАРМАСЬЮТИКАЛЗ, ИНК. Триазолопиридазиновые модуляторы протеинкиназ
BRPI0717320A2 (pt) * 2006-10-23 2013-10-22 Sgx Pharmaceuticals Inc Triazóis bicíclicos como moduladores de proteína cinase
CA2675755C (en) * 2007-01-19 2015-10-06 Xcovery, Inc. Pyridine and pyridazine derivatives as kinase inhibitors
WO2009055730A1 (en) * 2007-10-25 2009-04-30 Genentech, Inc. Process for making thienopyrimidine compounds
CN102015693B (zh) * 2008-02-21 2014-10-29 默沙东公司 作为erk抑制剂的化合物
ES2480994T3 (es) 2008-03-31 2014-07-29 Genentech, Inc. Compuestos de tipo benzopirano y benzoxepina inhibidores de PI3K y métodos de uso
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
US8263633B2 (en) 2009-09-28 2012-09-11 F. Hoffman-La Roche Ag Benzoxepin PI3K inhibitor compounds and methods of use
TWI423980B (zh) * 2009-09-28 2014-01-21 Hoffmann La Roche 苯并氧氮呯ｐｉ３ｋ抑制劑化合物及使用方法
CA2778684A1 (en) * 2009-10-29 2011-05-05 Schering Corporation Bridged bicyclic piperidine derivatives and methods of use thereof
CN102558167A (zh) * 2010-12-29 2012-07-11 中国医学科学院药物研究所 Gk和ppar双重激动活性的噻唑烷二酮衍生物
KR20140032383A (ko) 2011-03-21 2014-03-14 에프. 호프만-라 로슈 아게 Pi3k p110 델타에 대하여 선택적인 벤즈옥사제핀 화합물 및 이의 사용 방법
NO3175985T3 (enExample) * 2011-07-01 2018-04-28
CN104379163A (zh) 2012-06-08 2015-02-25 霍夫曼-拉罗奇有限公司 用于治疗癌症的磷酸肌醇3激酶抑制剂化合物和化疗剂的突变选择性及组合

Also Published As

Publication number Publication date
JP2016512209A (ja) 2016-04-25
AU2014230812A1 (en) 2015-09-03
CA2948763A1 (en) 2014-09-18
JP2020114814A (ja) 2020-07-30
CN105377856B (zh) 2018-05-22
RU2015138488A (ru) 2017-04-20
CA2948765A1 (en) 2014-09-18
JP2019089762A (ja) 2019-06-13
SG10201706760YA (en) 2017-10-30
RU2018109979A (ru) 2019-02-28
CN108929333A (zh) 2018-12-04
EP3404032A2 (en) 2018-11-21
AR095365A1 (es) 2015-10-14
CA3005118A1 (en) 2014-09-18
CA2948763C (en) 2018-04-24
WO2014140073A1 (en) 2014-09-18
CA2897618A1 (en) 2014-09-18
EP3404032A3 (en) 2019-03-13
KR20170070270A (ko) 2017-06-21
CA3005112A1 (en) 2014-09-18
AU2014230812A8 (en) 2015-09-10
EP3404032C0 (en) 2025-07-02
NZ711192A (en) 2019-04-26
KR20180070715A (ko) 2018-06-26
EP3845540B1 (en) 2026-07-22
JP6442005B2 (ja) 2018-12-19
CA3005103A1 (en) 2014-09-18
US20140275523A1 (en) 2014-09-18
JP2018008959A (ja) 2018-01-18
AU2018201393A1 (en) 2018-03-15
EP2970329A1 (en) 2016-01-20
US9303043B2 (en) 2016-04-05
KR101871133B1 (ko) 2018-06-25
HK1215433A1 (zh) 2016-08-26
MX2015011438A (es) 2016-02-03
RU2649976C2 (ru) 2018-04-06
JP2019031493A (ja) 2019-02-28
EP3845540A1 (en) 2021-07-07
AU2016204432B2 (en) 2017-12-07
IL240793A0 (en) 2015-10-29
JP2018150298A (ja) 2018-09-27
JP6363120B2 (ja) 2018-07-25
AU2016204432A1 (en) 2016-07-21
KR101821468B1 (ko) 2018-01-23
CN105377856A (zh) 2016-03-02
JP6663459B2 (ja) 2020-03-11
EP3404032B1 (en) 2025-07-02
BR112015020716A2 (pt) 2017-07-18
KR20150119033A (ko) 2015-10-23
SG11201507394RA (en) 2015-10-29

Similar Documents

Publication Publication Date Title
JP6663459B2 (ja) ベンゾオキサゼピン化合物の作製方法
US20240368167A1 (en) Heterobicyclic amides as inhibitors of cd38
KR20160012194A (ko) 이미다조피롤리디논 유도체 및 질환의 치료에서의 그의 용도
TW202220980A (zh) 新穎二唑系選擇性hdac6抑制劑
KR101698283B1 (ko) 티에노피리미딘 화합물의 제조 방법
IL211277A (en) Imidazolidine compounds as an androgen receptor modulator
WO2017060326A1 (en) Process for the preparation of (e)-3-(4-((e)-2-(2-chloro-4-fluorophenyl)-1-(1h-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid
CA2977752A1 (en) Benzimidazole compound for preventing or treating a disease caused by abnormal prs activity, method for preparing the same and pharmaceutical composition comprising the same
AU2024289347A1 (en) Nmt inhibitor, and preparation method therefor and use thereof
HK1215433B (en) Process for making benzoxazepin compounds
HK1244272B (en) Process for making thienopyrimidine compounds

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 29 , NO 34 , PAGE(S) 5136 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME GENENTECH, INC.; F. HOFFMANN-LA ROCHE AG, APPLICATION NO. 2014230812, UNDER INID (71) REMOVE CO-APPLICANT GENENTECH, INC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired